Trial Information
Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients
Inclusion Criteria:
- recurrent, metastatic esophageal SCC
- received either FP or XP as first-line chemotherapy.
Exclusion Criteria:
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Outcome Measure:
Overall Survival
Outcome Time Frame:
12 month
Safety Issue:
Yes
Principal Investigator
Jeeyun Lee, M.D., Ph.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Samsung Medical Center, Seoul, Korea
Authority:
South Korea: Institutional Review Board
Study ID:
SMCESOPROGNOSIS
NCT ID:
NCT01472419
Start Date:
March 2012
Completion Date:
March 2013
Related Keywords:
- Metastatic Esophageal Squamous Cell Carcinoma
- metastatic esophageal squamous cell carcinoma
- Fluoropyrimidine/platinum-based first-line chemotherapy
- prognosis
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Diseases